Dulaglutide has been assessed in several phase III trials, known as the global AWARD (Assessment of Weekly Administration of LY2189265 [dulaglutide] in diabetes) studies, showing that dulaglutide is generally an effective medication in maintaining glycemic control as monotherapy or if added to insulin or oral together with sustained weight loss and a low rate of hypoglycemia [5, 9, 13]. The gene discussed is INS; the disease is diabetes mellitus.